Drugs / F18 FBPA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07691775 | May → Dec 2026 expected | neoplasm | Heron Neutron Medical Corp. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F18 FBPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07691775 ↗ |
| Known as | 4-Borono-2-\[18F\]fluoro-L-phenylalanine | “F18 FBPA (4-Borono-2-\[18F\]fluoro-L-phenylalanine) is a radiolabeled phenylalanine analog used in positron emission tomography (PET) for tumor imaging.” NCT07691775 ↗ |
| Modality | Diagnostic / imaging agent | “used in positron emission tomography (PET) for tumor imaging” NCT07691775 ↗ |